RxDoctor Payments Data

Jaison Grimes, MD

Neurology · Indianapolis, INNPI 1588827026

Payments from drug & device makers

What this record shows

This record is dominated by consulting fees: $17,451 of the $22,115 with a category attached, or 78.9%. 4 manufacturers reported payments, led by EMD Serono, Inc. at 46.1% of the total. Reporting peaked in 2024 at $11,018 and has fallen 94.8% since, to $573 in 2025.

$22,115in general payments, 2019–2025

Across 61 payments — averaging $362.54 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • EMD Serono, Inc.$10K
  • TG Therapeutics, Inc.$9K
  • Novartis$3K
  • Corium, LLC$24
$167,906in research payments, 2019–2025

Across 25 payments — averaging $6716.25 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • AbbVie$109K
  • Biogen$31K
  • Mallinckrodt Enterprises LLC$20K
  • Mallinckrodt Hospital Products Inc.$9K

What the payments were for

  • Consulting fees$17,45179%
  • Travel & lodging$1,7148%
  • Food & beverage$2,95013%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
EMD Serono, Inc.6$10,199
TG Therapeutics, Inc.28$9,137
Novartis26$2,755
Corium, LLC1$24

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$22,115 in reported general payments places this provider in the 85th percentile of 308 neurology providers in Indiana.

See all neurology providers in Indiana

Medicare billing

Part B allowed, 2024
$132,475
Medicare patients
254
Services billed
13,275

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Rebif RebidoseInterferon Beta-1a/Albumin25$283,186
Kesimpta PenOfatumumab20$191,316
CopaxoneGlatiramer Acetate29$176,741
Gammagard LiquidImmun Glob G(Igg)/Gly/Iga Ov5017$165,523
Teriflunomide29$153,966
GilenyaFingolimod Hcl12$125,409
Glatiramer Acetate18$42,019
GlatopaGlatiramer Acetate23$34,066
MyrbetriqMirabegron16$12,478
Emgality PenGalcanezumab-Gnlm14$9,949
Dalfampridine ErDalfampridine22$6,181
FingolimodFingolimod Hcl26$5,644
Gabapentin148$2,488
AmantadineAmantadine Hcl30$2,463
Baclofen61$2,215

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
NovartisGilenya$2,755$125,40912 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 308 neurology providers in Indiana.

Other neurology in Indianapolis

See the full list for Indiana

Where these figures come from

Is this you, or does something look wrong? →